We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...
Pfizer’s PFE stock has risen 5.6% in the past month. This was due to the company’s encouraging guidance for 2025 issued in ...
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
Pfizer (NYSE: PFE) became a stock market star in early pandemic days as it brought the first coronavirus vaccine to market.
Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most ...
Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.
Then, this is the segment with the strongest focus in Pfizer's pipeline. If we take a look at the top 10 products in 2023, the ranking is still led by Comirnaty (19% weight), despite the drop in ...
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...
Citi analyst Geoff Meacham maintained a Hold rating on Pfizer (PFE – Research Report) today. The company’s shares closed yesterday at ...
Pfizer has had a difficult time in recent years as demand for its coronavirus products declined. The company’s share price has reflected the tough times, falling more than 50% over three years.
Sales of PFE’s COVID Products Declining Sales of Pfizer’s COVID products, Comirnaty and Paxlovid, are declining due to lower demand following the end of the pandemic. However, sales of both ...